Several lines of evidence outlined below lead us to speculate that PD-1- and/or CTLA-4-based immune checkpoint therapies may in fact not be the optimal way to manipulate anti-tumour immunity in the context of the specific immune microenvironmental and tumour cell features of ccRCC. The gene discussed is CTLA4; the disease is neoplasm.